Filspari denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for filspari are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Filspari for Medical Necessity — and How to Build Your Case

A medical-necessity denial for Filspari (sparsentan) means Aetna's reviewer concluded that the submitted clinical information did not satisfy all criteria in the plan's coverage policy for this drug in IgA nephropathy (IgAN). These criteria typically address diagnosis confirmation, disease severity or progression metrics, prior treatment history, and kidney function status. The denial does not mean Filspari is categorically excluded — it means the documentation submitted with the prior authorization did not check every required box. A focused appeal that maps chart evidence to each criterion is the correct response.

## Your Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): You are entitled to a full-and-fair internal review. The deadline is typically 180 days from the denial notice — check your specific notice.
• External review: If the internal appeal is denied, escalate to an independent external reviewer. The window is generally approximately four months from the original denial.
• Expedited review: If your kidney function is declining rapidly, this qualifies as an urgent condition — request expedited review for a faster decision timeline.

## Documentation to Gather

1. Biopsy-confirmed diagnosis — the pathology report confirming IgA nephropathy, with the date. 2. Disease severity documentation — proteinuria measurements over time (as recorded in chart notes or lab results), kidney function trajectory, and blood pressure control history, all showing the clinical picture your prescriber relies on. 3. Prior treatment history — any RAAS inhibitor or other optimized supportive therapy history with dates, doses as recorded, duration, and response or lack of response. 4. Prescriber medical-necessity letter — your nephrologist should explain why the clinical presentation meets the criteria in Aetna's policy, referencing the FDA-approved prescribing label and the applicable nephrology guideline organization (e.g., KDIGO) generically. 5. Specialist involvement — documentation confirming nephrology involvement in the care plan strengthens the appeal.

## Criteria-Mapping Structure

Obtain Aetna's published clinical policy for Filspari/sparsentan (available on Aetna's provider portal). Copy each criterion verbatim into a response table:

| Aetna Coverage Criterion | Chart Evidence Supporting Criterion | |---|---| | Biopsy-confirmed IgAN | [Pathology report date] | | Proteinuria level documented | [Lab result dates from chart — no cutoff stated here] | | Prior supportive therapy trial | [Medication history with dates] | | Nephrologist prescribing | [Prescriber specialty + NPI] | | On-label use | [FDA prescribing label citation] |

For each criterion, quote the exact chart fact. Attach the FDA prescribing label and the prescriber letter. Conciseness and direct criterion-by-criterion mapping are more persuasive than narrative length.